You are here

Programme at a Glance

Non-commercial satellite symposia on the occasion of the 53rd EASD Annual Meeting:

DateTimeCézanne HallEdison HallVerne HallMinot Hall
Sunday, 10 September 201714:30 - 17:30The REMOVAL trialIDF EuropePCDE & DESGFrom the cornea to the heart
Monday, 11 September 201714:30 - 17:00   EURADIA

 

Commercial satellite symposia on the occasion of the 53rd EASD Annual Meeting (links will open in a new window): 

 

Scientific programme of the 53rd EASD Annual Meeting:

Tuesday, 12 September 2017

 

Roma Hall

Lawrence Hall

Puccini Hall

Fitzgerald Hall

Fröbe Hall

Dürrenmatt Hall

Minot Hall

08:30 - 08:45

Opening Ceremony

 

 

 

 

 

 
08:45 - 09:15Presidential Address      
09:15 - 10:0049th Claude Bernard Lecture      

10:15 - 11:45

OP 1

OP 2

OP 3

OP 4

OP 5

OP 6

 

12:00 - 13:00

Poster Session A

 

13:15 - 14:15

Poster Session B 

14:30 - 16:00

OP 7

OP 8

OP 9

OP 10

OP 11

OP 12

 

16:15 - 17:15

32nd Camillo Golgi Lecture

11th Albert Renold Lecture

 

 

 

 

 

17:30 - 18:30

 

  

 

  EASD General Assembly

 

Wednesday, 13 September 2017

 

Roma Hall

Lawrence Hall

Puccini Hall

Fitzgerald Hall

Fröbe Hall

Dürrenmatt Hall

Cézanne Hall

08:30 - 10:00

Management of type 2 diabetes with basal insulin revisited: results of the glargine 300 U/ml Real Life Study Program

East-West Forum: diabetes outcome trends

EASD/ESC Symposium: Cardiovascular complications of diabetes: hot topics

Intergenerational transmission of obesity and diabetes: Is the fog being cleared?

The beta cell in type 2 diabetes: what are the changes and are they reversible?

EASD/ADA Symposium: Molecular transducers of metabolic benefits of exercise

Effects on the incidence of cardiovascular events of the add-on of pioglitazone as compared with a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin: the TOSCA.IT study

10:15 - 11:45

OP 13

OP 14

OP 15

OP 16

OP 17

OP 18

 

12:00 - 13:00

Poster Session C

13:15 - 14:15

Poster Session D

14:30 - 16:00

OP 19

OP 20

OP 21

OP 22

OP 23

OP 24

 

16:15 - 17:15

EASD-Novo Nordisk Foundation Diabetes Prize for Excellence

 

 

 

 

 

 

17:30 - 18:30

Acarbose Cardiovascular Evaluation (ACE): primary results

Dicarbonyl stress: from the bench to the clinicDiabetes, obesity, their treatment and cancer risk: smoke or fire?

Metformin diamond jubilee

Cognitive impairment and Alzheimer's disease in type 2 diabetes patient: from basic science to treatmentEASD/JDRF Symposium: Generation of stem cell-derived beta cells from type 1 diabetes patients 

 

Thursday, 14 September 2017

 

Roma Hall

Lawrence Hall

Puccini Hall

Fitzgerald Hall

Fröbe Hall

Dürrenmatt Hall

Cézanne Hall

08:30 - 10:00

Role of alirocumab in lipid management of individuals with  type 1 and  type 2 diabetes at high CV risk: ODYSSEY DM program

Neuroprotection: a new target for treating diabetic retinopathy

Hypoglycaemia revisitedMichael Berger debate: What do we have in the future of type 2 diabetes prediction and prevention?Central regulation of glucose metabolismMetabolism rocks around the clockSGLT2 inhibitors: novel therapies for type 1 diabetes

10:15 - 11:45

OP 25

OP 26

OP 27

OP 28

OP 29

OP 30

 

12:00 - 13:00

Poster Session E

13:15 - 14:15

Poster Session F

14:30 - 16:00

OP 31

OP 32

OP 33

OP 34

OP 35

OP 36

 

16:15 - 17:00

Induction of Honorary Members
52nd Minkowski Lecture

 

     

17:15 - 18:15

EXenatide Study of Cardiovascular Event Lowering (EXSCEL): primary results

Advances in infusion sets and insulin pumps

Calorie restriction: How does it affect metabolic functions?

New targets for prevention of diabetes complications

Immune modulation in the treatment of diabetesPrecision medicine in diabetes: How close are we? 

 

Friday, 15 September 2017

 

Roma Hall

Lawrence Hall

Puccini Hall

Fitzgerald Hall

Fröbe Hall

Dürrenmatt Hall

Cézanne Hall

08:30 - 09:30

Insulin degludec vs glargine cardiovascular safety in T2D: the DEVOTE study

Prevention of obesity-related pregnancy complications

Diabetes in primary care in EuropeObesity as a key driver for diabetes

Genome editing principle and practice: Is there opportunity for diabetes?

Diabetes and alpha cell function

Evolucumab in diabetes and diabetes risk: novelties from the FOURIER study

09:45 - 10:45

OP 37

OP 38

OP 39

OP 40

OP 41

OP 42

Continuous Glucose Monitoring before and during pregnancy in women with type 1 diabetes: results from CONCEPTT; a multicentre multinational randomised controlled trial

11:00 - 12:00

OP 43

OP 44

OP 45

OP 46

OP 47

OP 48

J-DOIT3: a multifactorial intervention trial for prevention of macrovascular complications and mortality
12:15 - 13:45CANagliflozin cardioVascular Assessment Study (CANVAS)Is the gut the answer to it all?The paradox of metabolically healthy obesity: Do we need better phenotyping?Organ specific vascular permeability in diabetesAdipose tissue, the link between insulin resistance and comorbidities?EASD/ERA-EDTA Symposium: New insights in diabetes nephropathyRising Star Symposium
13:45 - 13:55      

Please note: The programme may be subject to change